Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 3/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21878110 | 0.93 | CYP1A2 (0.44) | RAB9ASMN1; SMN2TP53NPC1MEN1 | |
| SCHEMBL21878037 | 0.85 | CYP1A2 (0.38) | MEN1KMT2ACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL21877939 | 0.80 | CYP1A2 (0.34) | MEN1KMT2ACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL21878046 | 0.78 | CYP1A2 (0.42) | MEN1KMT2ACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL21878114 | 0.77 | LMNA (0.37) | RAB9ASMN1; SMN2TP53NPC1MEN1 | |
| SCHEMBL21878032 | 0.75 | CCNA2 (0.41) | SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL21878033 | 0.75 | CCNA2 (0.41) | SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL21877942 | 0.75 | TBXA2R (0.42) | RAB9ASMN1; SMN2TP53NPC1MEN1 | |
| SCHEMBL20775997 | 0.73 | SMN1; SMN2 (0.64) | RAB9ASMN1; SMN2TP53NPC1MEN1 | |
| SCHEMBL21877941 | 0.73 | LMNA (0.43) | RAB9ASMN1; SMN2TP53NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | RAB9A 1267/4885SMN1; SMN2 1607/4885TP53 1417/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | RAB9A 1577/4885SMN1; SMN2 1544/4885TP53 1117/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | RAB9A 1381/4885SMN1; SMN2 1613/4885TP53 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.